51. 129P Newborn screening for spinal muscular atrophy in Poland – a summary of 3-year experience.
- Author
-
Gos, M., Wasiluk, J., Landowska, A., Jurzyk, M., Wawer, W., Kubiszyn, P., Wieczorek, J., Kordowska, O., Nosarieva, L., Durda, K., Fraczyk, M., Jedrzejowska, M., and Ołtarzewski, M.
- Subjects
- *
SPINAL muscular atrophy , *NEWBORN screening , *GENETIC testing , *ASYMPTOMATIC patients , *SYMPTOMS - Abstract
Spinal muscular atrophy (SMA) is a rare disorder that affects about 1/7000-8000 people in Poland. The disease can be successfully treated with available targeted drugs such as nusinersen, onasemnogene abeparvovec and risdiplam that are available from public funds for every SMA patient. The newborn screening for SMA has been implemented in March 2022 and since then it was implemented in whole country as a part of National Newborn Screening Programme. Herein, we present our three-year experience with SMA as a routine part of NBS. Newborn screening for SMA as a genetic test is not obligatory and parents have to consent for molecular testing (opt-in). Standard dried blood spots are used for DNA extraction and a PCR-HRM based test (SALSA MC002 SMA Newborn Screen test, MRC-Holland) is used for screening. After the positive result of first-tier test, we perform follow-up testing with MLPA technique (P021 kit, MRC-Holland). During 3 years, over 750 000 newborns were screened and SMA has been confirmed in 101 children that were admitted to regional children neurological clinics. The results of the first-tier test and MLPA verification from blood spot were ready on the 8th day of life (mean: 8.5±3.7; 3 days since registration in the central database). On the day 14th (mean 14.7±5.0; 9 days since registration), the results of the verification test were available. About 70% of diagnosed patients were asymptomatic, others presented mild symptoms of the disease. Three children with 1 SMN2 copy presented with SMA0. The treatment was implemented as soon as possible if patients were carrying from 1 to 3 SMN2 copies (2, 27 and 39 children, respectively). On average, therapy was started at 22nd day of life. The newborn screening for SMA was successfully implemented in Poland and became a part of the routine screening. Our procedure allows for quick identification of SMA patients that would benefit from targeted therapies. Based on the population data, the prevalence of SMA can be estimated at ≈1/7500. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF